Original from: businesswire
Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that it has entered a strategic collaboration with Merck KGaA, Darmstadt, Germany to develop FoundationOne®Liquid CDx and FoundationOne®CDx as companion diagnostics in the U.S. market for selected marketed and pipeline treatments. This new agreement builds on the data solutions partnership Merck KGaA, Darmstadt, Germany and Foundation Medicine entered in 2020 to help accelerate the development of novel targeted therapies, individually and in combination.
If the companion diagnostic indications are approved, based on tissue availability and the presentation of individual patients, oncologists will be able to use FoundationOne CDx or FoundationOne Liquid CDx to identify those with genomic alterations that may make them eligible for a specific targeted therapy.
¡°We¡¯re proud to announce this new phase of our partnership with Merck KGaA, Darmstadt, Germany, and continue building on our shared commitment to advance personalized treatment options for patients,¡± said Jason Adams, vice president of biopharma enterprise partnerships at Foundation Medicine. ¡°We look forward to ongoing collaboration as they leverage our portfolio of end-to-end solutions to generate meaningful evidence, help optimize therapy development, and deliver companion diagnostic solutions using our tissue and liquid comprehensive genomic profiling tests.¡±
Foundation Medicine¡¯s portfolio of FDA-approved comprehensive genomic profiling tests offer physicians both blood- and tissue-based testing options for detecting genomic alterations that help guide personalized treatment decisions. The company¡¯s robust suite of data and assay solutions support biopharmaceutical organizations as they work to design and deliver new targeted therapies, starting with biomarker discovery and clinical trial enrollment through to companion diagnostic development and commercialization.
